Novo Nordisk shares are trading lower after Britain's drug watchdog said it is probing a class of drugs that includes ozempic and saxenda.
Portfolio Pulse from Bill Haddad
Novo Nordisk's shares are trading lower following an announcement by Britain's drug watchdog that it is investigating a class of drugs that includes Novo's diabetes medicine Ozempic and weight-loss treatment Saxenda, due to reports of suicidal thoughts.
July 26, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's shares are expected to be negatively impacted in the short term due to the investigation by Britain's drug watchdog into Ozempic and Saxenda.
The investigation into Novo Nordisk's drugs Ozempic and Saxenda by Britain's drug watchdog is a significant regulatory issue that could potentially lead to a decrease in sales of these drugs, negatively impacting Novo Nordisk's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100